Immunization of pups with maternally derived antibodies to canine parvovirus (CPV) using a modified-live variant (CPV-2b).
The results of vaccination trials carried out on pups with maternally derived antibodies (MDA) to canine parvovirus (CPV), using a modified-live CPV-2b variant vaccine (29-97/40 strain), are reported. The vaccine was able to overcome the obstacle of MDA, and to elicit protective immunity in 100% of the pups whose antibody titres were 1:10-1:40, 83% of the pups with titres of 1:80, 57% of the pups with titres of 1:160, and even in 60% of the pups with antibody titres of 1:320.
Pratelli
A
A
Department of Health and Animal Welfare, Faculty of Veterinary Medicine, Bari, Italy.
Cavalli
A
A
Normanno
G
G
De Palma
M G
MG
Pastorelli
G
G
Martella
V
V
Buonavoglia
C
C
D000818:Animals; D000831:Animals, Newborn; D000914:Antibodies, Viral / Q000276:immunology*; D004283:Dog Diseases / Q000517:prevention & control*; D004285:Dogs; D005260:Female; D007112:Immunity, Maternally-Acquired / Q000276:immunology*; D010322:Parvoviridae Infections / Q000517:prevention & control / Q000662:veterinary*; D017993:Parvovirus, Canine / Q000145:classification / Q000276:immunology*; D014611:Vaccination / Q000662:veterinary; D014613:Vaccines, Attenuated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines